- Home
- / Cambium Bio
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Cambium Bio financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0
2024-06-07
Market Capitalization
$3.7 M
2024-06-07
Revenue
$670 K
FY, 2025
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| AUD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 575.0K | 1.7M | 7.1M | 129.0K | 670.0K | |||
| Gross profit | 2.7M | 1.4M | 4.2M | 8.1M | 638.0K | 1.0M | 177.0K | 1.2M |
| Gross profit margin, % | 476.5% | 254.9% | 114.5% | 137.2% | 177.2% | |||
| Operating expense total | 7.5M | 6.6M | 4.9M | 5.4M | 4.6M | 2.3M | 2.4M | 5.0M |
| Depreciation and amortization | 348.0K | 271.0K | 74.0K | 54.0K | 25.0K | 6.0K | 1.0K | 5.0K |
| EBITDA | (4.8M) | (5.2M) | (626.0K) | 2.7M | (4.0M) | (1.3M) | (2.2M) | (3.8M) |
| EBITDA margin, % | -842.8% | -37.6% | 38.4% | -1739.5% | -563.0% | |||
| EBIT | (5.2M) | (5.5M) | (718.0K) | 2.7M | (4.0M) | (1.3M) | (2.2M) | (3.8M) |
| EBIT margin, % | -903.3% | -43.2% | 37.7% | -1740.3% | -563.7% | |||
| Interest income | 35.0K | 19.0K | 1.0K | |||||
| Interest expense | 26.0K | 403.0K | 272.0K | 405.0K | 73.0K | 350.0K | 271.0K | 35.0K |
| Pre tax profit | (5.2M) | (6.0M) | (894.0K) | 2.8M | (4.3M) | (1.7M) | (2.3M) | (3.8M) |
| Net Income | (5.2M) | (6.0M) | (894.0K) | 2.8M | (4.3M) | (1.7M) | (2.3M) | (3.8M) |